Current Ratio

AstraZeneca’s current ratio stands at 0.91x, meaning the company has only $0.91 in current assets for every $1.00 of short-term liabilities — a measure of its ability to cover debts due within a year.

This is well below the healthcare sector median of 2.02x, placing the stock in the 10th percentile among sector peers, indicating a weaker liquidity profile compared to most competitors. No year-over-year or quarter-over-quarter changes are available, and no trend data exists for the last eight quarters, so an assessment of direction is not possible. The combination of a low current ratio with an unknown trend implies heightened short-term liquidity risk, as the company would need to rely on operational cash flow or external financing to meet near-term obligations. This metric contradicts the overall NEUTRAL verdict, as the low ratio points to a credit risk that could warrant a more cautious view, though the neutral rating may account for other compensating factors.

Frequently Asked Questions

Closest Sector Peers